Literature DB >> 18178092

1-deoxyrubralactone, a novel specific inhibitor of families X and Y of eukaryotic DNA polymerases from a fungal strain derived from sea algae.

Mitsuki Naganuma1, Masayuki Nishida, Kouji Kuramochi, Fumio Sugawara, Hiromi Yoshida, Yoshiyuki Mizushina.   

Abstract

Talaroflavone (1) and 1-deoxyrubralactone (2) are natural compounds isolated from cultures of a fungal strain derived from sea algae, and their structures were determined by spectroscopic analyses. Compound 2 is a novel rubralactone derivative, 6-hydroxy-8-methoxy-1-methyl-1,2,3a,9b-tetrahydrocyclopenta[c]isochromene-3,5-dione. These compounds selectively inhibited the activities of families X and Y of eukaryotic DNA polymerases (pols), and compound 2 was a stronger inhibitor than compound 1. The IC(50) values of compound 2 on rat pol beta, which is a pol of family X, and human pol kappa, which is a pol of family Y, were 11.9 and 59.8 microM, respectively. On the other hand, compounds 1 and 2 did not influence the activities of the other families of eukaryotic pols, such as family A (i.e., pol gamma) and family B (i.e., pols alpha, delta, and epsilon), and showed no effect even on the activities of plant pols alpha and beta, prokaryotic pols, and other DNA metabolic enzymes, such as calf primase of pol alpha, human immunodeficiency virus type-1 (HIV-1) reverse transcriptase, human telomerase, T7 RNA polymerase, mouse IMP dehydrogenase (type II), human topoisomerase I and II, T4 polynucleotide kinase, and bovine deoxyribonuclease I. This is the first report about the selective inhibitors of families X and Y of eukaryotic pols.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18178092     DOI: 10.1016/j.bmc.2007.12.044

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Targeting DNA polymerase ß for therapeutic intervention.

Authors:  Eva M Goellner; David Svilar; Karen H Almeida; Robert W Sobol
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

Review 2.  Exploring the Mangrove Fruit: From the Phytochemicals to Functional Food Development and the Current Progress in the Middle East.

Authors:  Fitri Budiyanto; Eman A Alhomaidi; Afrah E Mohammed; Mohamed A Ghandourah; Hajer S Alorfi; Nahed O Bawakid; Wailed M Alarif
Journal:  Mar Drugs       Date:  2022-04-28       Impact factor: 6.085

Review 3.  Biological and therapeutic relevance of nonreplicative DNA polymerases to cancer.

Authors:  Jason L Parsons; Nils H Nicolay; Ricky A Sharma
Journal:  Antioxid Redox Signal       Date:  2012-09-05       Impact factor: 8.401

4.  Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria sp. NH-F6.

Authors:  Hui Ding; Dashan Zhang; Biao Zhou; Zhongjun Ma
Journal:  Mar Drugs       Date:  2017-03-16       Impact factor: 5.118

Review 5.  Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action.

Authors:  Alejandro M S Mayer; Abimael D Rodríguez; Roberto G S Berlinck; Nobuhiro Fusetani
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2010-09-15       Impact factor: 3.228

6.  3-O-methylfunicone, a selective inhibitor of mammalian Y-family DNA polymerases from an Australian sea salt fungal strain.

Authors:  Yoshiyuki Mizushina; Hirohisa Motoshima; Yasuhiro Yamaguchi; Toshifumi Takeuchi; Ken Hirano; Fumio Sugawara; Hiromi Yoshida
Journal:  Mar Drugs       Date:  2009-11-23       Impact factor: 5.118

Review 7.  Translesion synthesis inhibitors as a new class of cancer chemotherapeutics.

Authors:  Seema M Patel; Radha Charan Dash; M Kyle Hadden
Journal:  Expert Opin Investig Drugs       Date:  2020-12-03       Impact factor: 6.206

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.